Genomic Valley Biotech Ltd

The next results date for Genomic Valley is 15 October 2025.

Genomic Valley's historical performance has shown significant fluctuations, with net sales peaking at 2.72 Cr in March 2023 before declining to 0.84 Cr by March 2025, alongside decreases in operating profit, profit before tax, and earnings per share. Overall, the company's financial metrics reflect volatility with notable peaks followed by declines.

The next results date for Genomic Valley is August 7, 2025.

As of 24th July, Genomic Valley Biotech Ltd has a market capitalization of 15.00 Cr, with net sales of 0.85 Cr and a net profit of 0.36 Cr reported in the latest four quarters. The balance sheet for March 2024 shows shareholder's funds of 3.54 Cr and total assets of 4.33 Cr.

Genomic Valley Biotech Ltd is a micro-cap company focused on biotechnology research and the commercial production of plant tissue cultured plants. As of March 2025, it reported net sales of 3 Cr and a net loss of 1 Cr, with a market cap of INR 15 Cr.

As of March 2022, the management team of Genomic Valley includes Yogesh Agrawal (Chairman & Managing Director), Parul Agrawal (Director), Gupta Pradeep (Independent Director), Jyoti Bansal (Additional Director), and Praveen Kumar Mishra (Additional Director). Only Yogesh Agrawal has specified remuneration of 5.5 lacs INR.

As of May 26, 2025, Genomic Valley's technical trend has shifted to bearish, supported by bearish signals from the MACD, KST, and moving averages, while the RSI indicates a lack of momentum.

As of May 26, 2025, Genomic Valley's technical trend has shifted to bearish, supported by bearish signals from the MACD, KST, and moving averages, while the RSI indicates a lack of momentum.

The top shareholders of Genomic Valley are Yogesh Agrawal with 46.72%, and Deepti Aggarwal, the largest public shareholder, with 11%. Individual investors collectively own 52.62% of the shares, with no institutional holdings or pledged promoter shares reported.

Peers of Genomic Valley include Sun Pharma, Divi's Lab, Cipla, and Dr Reddy's Labs, among others. Divi's Lab has the highest 1-year return at 51.96%, while Genomic Valley's return is 29.73%, lower than Divi's but higher than Decipher Labs' -37.27%.

As of 05-Jun, Genomic Valley Biotech Ltd's stock price is Rs 48.00, up 3.78% over the last two days, but down 39.24% year-to-date. Despite recent gains, the stock has significantly underperformed compared to the Sensex and remains below several moving averages, though increased investor participation may indicate potential recovery interest.